Extremity Medical, LLC, of Parsippany, New Jersey, announces the release of its next generation viable bone cell graft for use in surgery on the foot, ankle, wrist and hand—BioFuse. According to the firm’s press release, this live cell graft supplies the physiologic and essential components needed for robust bone formation. Among them are osteogenic cells, osteoinductive (biologic stimulants), and an osteoconductive (scaffold).
Matt Lyons’ Venture, Extremity Medical, Next Gen Bone Cell Graft
1 min read Premium comments
Secondary
Company officials state that the company utilizes proprietary processing advancements focused on providing faster harvesting, and a significant reduction in the exposure to harmful stressors that can damage cells during processing.
The company maintains that, in vitro testing indicates that BioFuse provides higher levels of osteoinductive biologic stimulants, and increased osteoconductivity as compared to traditionally processed live bone cell grafts.
Matt Lyons, Chairman and CEO of Extremity Medical commented, “BioFuse is a next generation viable bone matrix that will have a significant impact on the bone graft market for the extremities. This addition to the growing Extremity Medical portfolio will complement our current and planned product portfolio for 2017 and beyond and aligns with our continued goal to release innovative products that will significantly impact the extremity surgeon’s ability to treat challenging patient conditions.”
React:
Discussion
This is a fascinating development. In my practice we've seen similar outcomes with the revised protocol. The key differentiator seems to be patient selection criteria. Has anyone else noticed the correlation with BMI thresholds?
Great point. I'd push back slightly on the conclusion, the sample size in the cited study is too small to draw population-level inferences. That said, the directional signal is compelling and worth a larger RCT.
We implemented a similar approach last year. Early results are promising but we're still gathering 12-month follow-up data. Happy to share our protocol if anyone is interested.
Join the conversation
Orthopedic professionals are discussing this. Sign in and upgrade to read every comment and add your voice.